MedTrace Logo

Nonmyeloablative Allogeneic Transplant

NCT01272817 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2022-11-23

No results posted yet for this study

Summary

Allogeneic transplant from a matched sibling for the treatment of a variety of illnesses including bone marrow failure states, leukemias, myelodysplastic or myeloproliferative syndromes, lymphoma, or myeloma using a nonmyeloablative preparative regimen.

Conditions

Interventions

PROCEDURE

Nonmyeloablative Allogeneic Transplant

Cladribine 0.14 mg/kg/day for five days, melphalan 100 mg/m2 on one day

PROCEDURE

Nonmyeloablative Allogeneic Transplant

Total lymphoid irradiation 100cGy/day times 10 days (Monday through Friday)

Sponsors & Collaborators

  • Scripps Health

    lead OTHER

Principal Investigators

  • Jeffrey W. Andrey, M.D. · Scripps Health

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
72 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-10-31
Primary Completion
2015-10-31
Completion
2015-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01272817 on ClinicalTrials.gov